Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:6:p17
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 6 (pt 17/36)
Character Range: 357142–360241

less of eprinomectin except when included in Schedule 5.
    EPTC.
    ESBIOTHRIN except:

       (a) when included in Schedule 5; or

       (b) in pressurised spray packs containing 1% or less of esbiothrin.
    ESFENVALERATE except when included in Schedule 5.
    ETHEPHON (excluding its salts and derivatives).
    ETHER except:

       (a) when included in Schedule 2, 4 or 5; or

       (b) in preparations containing 10% or less of ether.
    ETHIOFENCARB.
    ETHOATE‑METHYL.
    ETHOPROPHOS in granular formulations containing 10% or less of ethoprophos and 2% of linseed oil.
    ETHYL BROMIDE.
    ETHYLENE CHLOROHYDRIN.
    ETHYLENE DICHLORIDE.
    ETHYLENE GLYCOL (excluding its salts and derivatives) except:

       (a) when included in Schedule 5; or

       (b) in paints or paint tinters; or

       (c) in toothpastes or mouthwashes containing more than 0.25% of ethylene glycol; or

       (d) in other preparations containing 2.5% or less of ethylene glycol.
    ETHYLENE GLYCOL MONOALKYL ETHERS and their acetates, except:

       (a) when separately specified in these Schedules; or

       (b) in preparations containing 10% or less of such substances.
    ETHYL FORMATE when packed and labelled for use as a fumigant.
    ETHYLHEXANEDIOL except in preparations containing 5% or less of ethylhexanediol.
    2‑ETHYLHEXANOIC ACID and its alkyl esters except in preparations containing 5% or less calculated as 2‑ethylhexanoic acid.
    ETRIMFOS.
    EUCALYPTUS OIL except:

       (a) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

       (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and compliant with the requirements of the required advisory statements for medicine labels; or

       (c) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and labelled with the warnings:

          (i) KEEP OUT OF REACH OF CHILDREN; and

          (ii) NOT TO BE TAKEN; or

       (d) in preparations other than medicines for human therapeutic use, when packed in containers having a nominal capacity of 25 mL or less fitted with a restricted flow insert and a child‑resistant closure and labelled with the warnings:

          (i) KEEP OUT OF REACH OF CHILDREN; and

          (ii) NOT TO BE TAKEN; or

       (e) in preparations containing 25% or less of eucalyptus oil.
    EUGENOL except:

       (a) when included in Schedule 5; or

       (b) in medicines for human therapeutic use, when packed in containers having a nominal capacity of 15 mL or less fitted with a restricted flow insert and compliant with the requirements of the required advisory statements for medicine labels; or

       (c) in medicines for human therapeutic